Minerva Neurosciences Inc (NERV) - Total Assets
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) holds total assets worth $28.09 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NERV net assets for net asset value and shareholders' equity analysis.
Minerva Neurosciences Inc - Total Assets Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's total assets have evolved over time, based on quarterly financial data.
Minerva Neurosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Minerva Neurosciences Inc's total assets of $28.09 Million consist of 60.0% current assets and 40.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.85 Billion | 39992.0% |
| Goodwill | $14.87 Million | 40.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Minerva Neurosciences Inc (NERV) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Minerva Neurosciences Inc's current assets represent 60.0% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 57.5% of total assets in 2024, down from 95.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40032.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 39992.0% of total assets.
Minerva Neurosciences Inc Competitors by Total Assets
Key competitors of Minerva Neurosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Minerva Neurosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.87 | 6.23 | 8.68 |
| Quick Ratio | 4.87 | 6.23 | 8.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.35 Million | $23.45 Million | $24.28 Million |
Minerva Neurosciences Inc - Advanced Valuation Insights
This section examines the relationship between Minerva Neurosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | -34.7% |
| Total Assets | $37.14 Million |
| Market Capitalization | $26.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Minerva Neurosciences Inc's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Minerva Neurosciences Inc's assets decreased by 34.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Minerva Neurosciences Inc (2012–2024)
The table below shows the annual total assets of Minerva Neurosciences Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $37.14 Million | -34.72% |
| 2023-12-31 | $56.90 Million | +3.29% |
| 2022-12-31 | $55.09 Million | -28.57% |
| 2021-12-31 | $77.12 Million | +33.83% |
| 2020-12-31 | $57.63 Million | -25.64% |
| 2019-12-31 | $77.50 Million | -44.30% |
| 2018-12-31 | $139.14 Million | -24.26% |
| 2017-12-31 | $183.70 Million | +38.18% |
| 2016-12-31 | $132.94 Million | +60.99% |
| 2015-12-31 | $82.58 Million | +20.64% |
| 2014-12-31 | $68.45 Million | +134.62% |
| 2013-12-31 | $29.17 Million | +13838.62% |
| 2012-12-31 | $209.31K | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more